SEC Comment Letter 0000000000-25-011914 to Rein Therapeutics, Inc. (RNTX)

Rein Therapeutics, Inc.
Date: Dec. 31, 2025 · CIK: 0001420565 · Accession: 0000000000-25-011914

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

December 31, 2025

Author

Brian Windsor, Ph.D.

Form

UPLOAD

Company

Rein Therapeutics, Inc.

Letter

December 31, 2025 Brian Windsor, Ph.D. President and Chief Executive Officer Rein Therapeutics, Inc. 12407 N. Mopac Expy., Suite 250 #390 Austin, Texas 78758 Re:Rein Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted December 29, 2025 CIK 0001420565 Dear Brian Windsor, Ph.D.: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Daniel K. Donahue

Show Raw Text

December 31, 2025
Brian Windsor, Ph.D.
President and Chief Executive Officer
Rein Therapeutics, Inc.
12407 N. Mopac Expy., Suite 250 #390
Austin, Texas 78758
Re:Rein Therapeutics, Inc.
Draft Registration Statement on Form S-1
Submitted December 29, 2025
CIK 0001420565
Dear Brian Windsor, Ph.D.:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement and non-public draft
submission on EDGAR at least two business days prior to the requested effective date and
time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Daniel K. Donahue

SecProbe.io